Name	Marc H.G.P. Raaijmakers
Current Position & Affiliation	-Professor of Hematology and deputy chair of the Department of Hematology at the Erasmus MC Cancer Institute, Rotterdam -Visiting professor at the Center for Hematology and Regenerative Medicine (HERM) at the Karolinska Institutet (2023). Chair: Stem cell niche biology. -Deputy-chair HOVON trial organization -Deputy chair HOVON Leukemia Working Group (an international collaborative working
Country	The Netherlands
Major Field	Bone marrow failure, MDS, AML and genetic predisposition for myeloid malignancies

Educational Background

Marc H.G.P. Raaijmakers, MD, PhD is a clinical hematologist and full professor of Hematology in the Department of Hematology at the Erasmus MC Cancer Institute, Rotterdam, the Netherlands. He received his MD from the University Utrecht and clinical training in Internal Medicine and Hematology at the Radboud University Hospital in Nijmegen and Brigham &Women Hospital, Harvard Medical School, Boston U.S.A. He completed postdoctoral research at the Department of Stem Cell and Regenerative Biology at Harvard University. His clinical focus is in the management of patients with leukemia predisposition syndromes (including genetic predisposition syndromes, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), leading global, label-enabling, phase-3 clinical trials on targeted therapy in AML. His laboratory studies micro-environmental contributions to stem cell regulation and transformation, with an emphasis on the initiation, evolution and treatment of myeloid malignancies. The work revealed a concept of niche-induced oncogenesis in the hematopoietic system and made pivotal contributions to our understanding of the underlying mechanisms and the origins of stem cell niches in the bone marrow. He (co)-authored papers and comments in leading journals including *Nature*, *Cell*, *Cell Stem Cell*, *J. Exp. Med*, *Blood, Leukemia* and *Nature Communications*, served in the editorial boards of leading journals in the field of Hematology and provided numerous invited lectures at international meetings, including (keynote) lectures at national societies of Hematology (U.S.A., France, Germany, Spain and Japan), EMBO and FASEB. He received scholar awards and funding from many organizations, including the Dutch Cancer Society, the Dutch Society of Hematology, the Dutch Ministry of Science and Innovation, Worldwide Cancer Research and the Leukemia & Lymphoma Society U.S.A.

Professional Experience

Current affiliations:

- Deputy-head department of Hematology, Erasmus MC Cancer Institute
- Visiting professor at the Center for Hematology and Regenerative Medicine (HERM) at the Karolinska Institutet (2023). Chair: Stem cell niche biology.
- Deputy-chair HOVON trial organization
- Deputy chair HOVON Leukemia Working Group (an international collaborative working group performing investigator-initiated clinical trials in MDS and AML)

- Global Principal Investigator HOVON-sponsored phase III international, label-enabling, clinical trial in *FLT3*-mutated AML (gilteritinib vs. standard-of-care).
- Global Principal Investigator HOVON-sponsored phase III international, label-enabling, clinical trial in *NPM1*-mutated and *KMT2A*-rearranged AML (bleximenib vs. standard-of-care).

Other Experience and Professional Memberships

- Chair NFU (Dutch Federation of Universities) expertise Center on Genetic Predisposition fin Leukemia
- Chair European Hematology Association (EHA) scientific working group on Genetic Predisposition in Hematologic Cancer
- Chair Dutch Cancer Society (KWF) scientific assessment committee ('Beoordelingscommisie Exploratie')(2019-2024)
- Member of international scientific boards/advisory committees for both professional and patient-driven organizations, including the Specialized Working Group committee of the EHA, the scientific advisory Board of the European School of Hematology (ESH), the RUNX1 Foundation USA, Shwachman-Diamond Syndrome Alliance and the Institut Leucemie Paris Saint-Louis.

Main Scientific Publications

1. Raaijmakers MH, Scadden DT. 2008. Divided within: heterogeneity within adult stem cell pools. *Cell* 135(6):1006-8, 2. Raaijmakers MHGP*, Mukherjee S, ... DT Scadden*. Osteoprogenitor cell dysfunction induces myelodysplasia and secondary leukemia. *Nature* 2010 Apr 8;464 (7290):852-7(* corresponding authors), 3. Raaijmakers MHGP. Disease progression in myelodysplastic syndromes: do mesenchymal cells pave the way? *Cell Stem Cell* 2014 Jun 5;14(6):695-7, 4. Zambetti NA, Ping Z, Chen S, ..., Raaijmakers. MHGP. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. *Cell Stem Cell* 2016 Nov 3;19(5):613-627, 5. Pronk E, Raaijmakers MHGP. The mesenchymal niche in MDS. *Blood* 2019 Mar 7;133(10):1031-1038, 6. Raaijmakers MHGP. Aging of the Hematopoietic Stem Cell Niche: An Unnerving Matter. *Cell Stem Cell* 2019 Sep 5;25(3):301-303. 7. Kenswil KJG, Pisterzi P, Sánchez-Duffhues, ... Raaijmakers MHGP. endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. *Cell Stem Cell* 2021 Apr 1;28(4):653-670. 8. Feyen J, ... Raaijmakers MHGP. Myeloid cells promote interferon signaling-associated deterioration of the hematopoietic system. *Nature Commun*. 2022 Dec 10;13(1):7657.
9. Chen L, Bian Y, ...Raaijmakers MHGP. An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome. *Nat Commun*. 2025 Nov 18;16(1):10041. doi: 10.1038/s41467-025-65802-z.